Extended Data Table 2 Gastrointestinal adverse events by sex and time (safety population)

From: Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

  1. DB, double-blind; OL, open-label.
Back to article page